![[Video] The Weekly Break Out Ep. 19: Army aviation’s shakeup and the F-35’s future](https://breakingdefense.com/wp-content/uploads/sites/3/2025/05/EP-19-THUMB-play-button.jpg?#)
FDA Approves Brekiya (dihydroergotamine mesylate) Injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
BRIDGEWATER, N.J., May 15, 2025 -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya (dihydroergotamine mesylate)...
BRIDGEWATER, N.J., May 15, 2025 -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya (dihydroergotamine mesylate)...
